TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))

Docket No. 31162

In Re Application Of: Gustavo C. Rodriguez

Serial No.

Filing Date

Examiner

Group Art Unit

09/528,963

March 21, 2000

J. Goldberg

1614

Title: PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF PRODUCTS THAT INDUCE TRANSFORMING GROWTH FACTOR-BETA AND/OR APOPTOSIS IN THE OVARIAN EPITHELIUM



Address to:

Assistant Commissioner for Patents Washington, D.C. 20231

RECEIVED

JUN 2 7 20010

37 CFR 1.97(b)

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

- 2. The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:
 - 1. a Final Action under 37 CFR 1.113, or
 - 2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

a certification as specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

Copyright 1996 Legalsoft

P10A/REV01



CERTIFICATE OF MAILING

I, Raymond N. Nimrod, hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on June 21, 2000.

Dated: June 21, 2000

Raymond N. Nimrod



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: GUSTAVO RODRIGUEZ)	
	No.: 09/528,963))	Group Art Unit: 1614
	March 21, 2000)	
)	
For:	PREVENTION OF OVARIAN CANCER)	
	BY ADMINISTRATION OF PRODUCTS)	
	THAT INDUCE TRANSFORMING)	
	GROWTH FACTOR-BETA AND/OR)	
	APOPTOSIS IN THE OVARIAN)	
	EPITHELIUM)	

INFORMATION DISCLOSURE STATEMENT

To: Assistant Commissioner For Patents

Washington, DC. 20231

Sir:

The following is a disclosure of art which is being filed within three months of the filing date of the application.

The references submitted for consideration by the Office are set forth on the enclosed PTO Forms 1449 (20 pages). Legible copies of the references are included herewith.

This Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited in this statement is, or is considered to

be, material to patentability as defined in §1.56(b) or that no other information material to patentability as defined in 37 C.F.R. §1.56(b) exists.

Respectfully submitted,

Raymond N. Nimrod Reg. No. 31,987

ROPER & QUIGG 200 South Michigan Avenue Suite 1000 Chicago, Illinois 60604 (312) 408-0855

CERTIFICATE OF MAILING

I, Raymond N. Nimrod, hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on June 21, 2000.

Dated: June 21, 2000

Raymond N. Nimrod